{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:29:43Z","timestamp":1791930583919,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T00:00:00Z","timestamp":1483574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T00:00:00Z","timestamp":1483574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diabetes has emerged as a threat to the current world. More than ninety five per cent of all the diabetic population has type 2 diabetes mellitus (T2DM). Aggregates of Amylin hormone, which is co-secreted with insulin from the pancreatic \u03b2-cells, inhibit the activities of insulin and glucagon and cause T2DM. Importance of the conformationally restricted peptides for drug design against T2DM has been invigorated by recent FDA approval of Symlin, which is a large conformationally restricted peptide. However, Symlin still has some issues including solubility, oral bioavailability and cost of preparation. Herein, we introduced a novel strategy for conformationally restricted peptide design adopting a minimalistic approach for cost reduction. We have demonstrated efficient inhibition of amyloid formation of Amylin and its disruption by a novel class of conformationally restricted \u03b2-sheet breaker hybrid peptidomimetics (BSBHps). We have inserted \u03b2, \u03b3 and \u03b4 -aminobenzoic acid separately into an amyloidogenic peptide sequence, synthesized \u03b1\/\u03b2, \u03b1\/\u03b3 and \u03b1\/\u03b4 hybrid peptidomimetics, respectively. Interestingly, we observed the aggregation inhibitory efficacy of \u03b1\/\u03b2 and \u03b1\/\u03b3 BSBHps, but not of \u03b1\/\u03b4 analogues. They also disrupt existing amyloids into non-toxic forms. Results may be useful for newer drug design against T2DM as well as other amyloidoses and understanding amyloidogenesis.<\/jats:p>","DOI":"10.1038\/srep40095","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T11:28:32Z","timestamp":1483615712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Disaggregation of Amylin Aggregate by Novel Conformationally Restricted Aminobenzoic Acid containing \u03b1\/\u03b2 and \u03b1\/\u03b3 Hybrid Peptidomimetics"],"prefix":"10.1038","volume":"7","author":[{"given":"Ashim","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Kalita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan","family":"Kalita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piruthivi","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhubaneswar","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"key":"BFsrep40095_CR1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrm3810","volume":"15","author":"TPJ Knowles","year":"2014","unstructured":"Knowles, T. P. J., Vendruscolo, M. & Dobson, C. M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384\u2013396 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFsrep40095_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrd3050","volume":"9","author":"A Aguzzi","year":"2010","unstructured":"Aguzzi A. & O\u2019Conno, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discovery, 9, 237\u2013248 (2010).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"BFsrep40095_CR3","doi-asserted-by":"crossref","first-page":"11738","DOI":"10.1021\/ja063751v","volume":"13","author":"AM Squires","year":"2006","unstructured":"Squires, A. M. et al. X-ray scattering study of the effect of hydration on the cross-beta structure of amyloid fibrils. J. Am. Chem. Soc. 13, 11738\u201311739 (2006).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep40095_CR4","doi-asserted-by":"crossref","first-page":"14686","DOI":"10.1021\/ja203736z","volume":"133","author":"JR Lewandowski","year":"2011","unstructured":"Lewandowski, J. R. et al. Structural Complexity of a Composite Amyloid Fibril. J. Am. Chem. Soc. 133, 14686\u201314698 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep40095_CR5","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1021\/bi00145a001","volume":"31","author":"PT Lansbury Jr.","year":"1992","unstructured":"Lansbury, P. T. Jr. In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry, 31, 6865\u20136870 (1992).","journal-title":"Biochemistry"},{"key":"BFsrep40095_CR6","doi-asserted-by":"crossref","first-page":"21274","DOI":"10.1038\/srep21274","volume":"6","author":"EH Pilkington","year":"2016","unstructured":"Pilkington, E. H. et al. Pancreatic \u03b2-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide Species. Sci Rep. 6, 21274 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep40095_CR7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00042.2009","volume":"91","author":"P Westermark","year":"2011","unstructured":"Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795\u2013826 (2011).","journal-title":"Physiol. Rev."},{"key":"BFsrep40095_CR8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1097-0282(2001)60:6<438::AID-BIP10182>3.0.CO;2-A","volume":"60","author":"A Kapurniotu","year":"2001","unstructured":"Kapurniotu, A. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers, 60, 438\u2013459 (2001).","journal-title":"Biopolymers"},{"key":"BFsrep40095_CR9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/ar200189b","volume":"45","author":"JR Brender","year":"2012","unstructured":"Brender, J. R., Salamekh, S. & Ramamoorthy, A. Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective. Acc. Chem. Res. 45, 454\u2013462 (2012).","journal-title":"Acc. Chem. Res."},{"key":"BFsrep40095_CR10","doi-asserted-by":"crossref","first-page":"11338","DOI":"10.1021\/bi020314u","volume":"41","author":"M Anguiano","year":"2002","unstructured":"Anguiano, M., Nowak, R. J. & Lansbury, P. T. Jr. Protofibrillar Islet Amyloid Polypeptide Permeabilizes Synthetic Vesicles by a Pore-like Mechanism that May Be Relevant to Type II Diabetes. Biochemistry, 41, 11338\u201311343 (2002).","journal-title":"Biochemistry"},{"key":"BFsrep40095_CR11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.chembiol.2005.05.010","volume":"12","author":"MT Nossol","year":"2005","unstructured":"Nossol, M. T. et al. Inhibition of hIAPP amyloid-fibril formation and apoptotic cell death by a designed hIAPP amyloid-core-containing hexapeptide. Chem. Biol. 12, 797\u2013809 (2005).","journal-title":"Chem. Biol."},{"key":"BFsrep40095_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jmb.2011.12.062","volume":"421","author":"T Hard","year":"2012","unstructured":"Hard, T. & Lendel, C. Inhibition of amyloid formation. J. Mol. Biol. 421, 441\u2013465 (2012).","journal-title":"J. Mol. Biol."},{"key":"BFsrep40095_CR13","doi-asserted-by":"crossref","first-page":"13434","DOI":"10.1039\/C5CC05264E","volume":"51","author":"K Rajasekhar","year":"2015","unstructured":"Rajasekhar, K., Chakrabarti, M. & Govindaraju, T. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer\u2019s disease. Chem. Commun. 51, 13434\u201313450 (2015).","journal-title":"Chem. Commun."},{"key":"BFsrep40095_CR14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1006\/jmbi.1999.3422","volume":"295","author":"K Tenidis","year":"2000","unstructured":"Tenidis, K. et al. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J. Mol. Biol. 295, 1055\u20131071 (2000).","journal-title":"J. Mol. Biol."},{"key":"BFsrep40095_CR15","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P. et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87, 5036\u20135040 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep40095_CR16","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1021\/ja072157y","volume":"129","author":"A Abedini","year":"2007","unstructured":"Abedini, A., Meng, F. & Raleigh, D. P. A Single-Point Mutation Converts the Highly Amyloidogenic Human Islet Amyloid Polypeptide into a Potent Fibrillization Inhibitor. J. Am. Chem. Soc. 129, 11300\u201311301 (2007).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep40095_CR17","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1002\/anie.200353565","volume":"43","author":"S Gilead","year":"2004","unstructured":"Gilead, S. & Gazit, E. Inhibition of Amyloid Fibril Formation by Peptide Analogues Modified with \u03b1-Aminoisobutyric Acid. Angew. Chem. Int. Ed. 43, 4041\u20134044 (2004).","journal-title":"Angew. Chem. Int. Ed."},{"key":"BFsrep40095_CR18","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1039\/c3cc38982k","volume":"49","author":"A Mishra","year":"2013","unstructured":"Mishra, A. et al. Conformationally restricted short peptides inhibit human islet amyloid polypeptide (hIAPP) fibrillization. Chem Commun. 49, 2688\u20132690 (2013).","journal-title":"Chem Commun."},{"key":"BFsrep40095_CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/jmbi.2001.5244","volume":"315","author":"A Kapurniotu","year":"2002","unstructured":"Kapurniotu, A., Schmauder, A. & Tenidis K. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J. Mol. Biol. 315, 339\u2013350 (2002).","journal-title":"J. Mol. Biol."},{"key":"BFsrep40095_CR20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn500064z","volume":"5","author":"KC Nadimpally","year":"2014","unstructured":"Nadimpally, K. C., Paul, A. & Mandal, B. Reversal of Aggregation Using \u03b2-Breaker Dipeptide Containing Peptides: Application to A\u03b2(1\u201340) Self-Assembly and Its Inhibition. ACS Chem. Neurosci. 5, 400\u2013408 (2014).","journal-title":"ACS Chem. Neurosci"},{"key":"BFsrep40095_CR21","doi-asserted-by":"crossref","first-page":"17743","DOI":"10.1021\/ja804297f","volume":"130","author":"P Pravakaran","year":"2008","unstructured":"Pravakaran, P. et al. Sequence-Specific Unusual (1\u21922)-Type Helical Turns in \u03b1\/\u03b2-Hybrid Peptides. J. Am. Chem. Soc. 130, 17743\u201317754 (2008).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep40095_CR22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/cg201268x","volume":"12","author":"S Maity","year":"2012","unstructured":"Maity, S. et al. Conformational Heterogeneity, Self-Assembly, and Gas Adsorption Studies of Isomeric Hybrid Peptides. Cryst. Growth. Des. 12, 422\u2013428 (2012).","journal-title":"Cryst. Growth. Des."},{"key":"BFsrep40095_CR23","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1039\/C4CC09063B","volume":"51","author":"A Paul","year":"2015","unstructured":"Paul, A. et al. Inhibition of Alzheimer\u2019s amyloid-\u03b2 peptide aggregation and its disruption by a conformationally restricted \u03b1\/\u03b2 hybrid peptide. Chem. Commun. 51, 2245\u20132248 (2015).","journal-title":"Chem. Commun."},{"key":"BFsrep40095_CR24","doi-asserted-by":"crossref","first-page":"17444","DOI":"10.1021\/ja308371z","volume":"134","author":"SW Haynes","year":"2012","unstructured":"Haynes, S. W. et al. Assembly of Asperlicin Peptidyl Alkaloids from Anthranilate and Tryptophan: A Two-Enzyme Pathway Generates Heptacyclic Scaffold Complexity in Asperlicin E. J. Am. Chem. Soc. 134, 17444\u201317447 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep40095_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-894X(98)00696-9","volume":"9","author":"VB Oza","year":"1999","unstructured":"Oza, V. B. et al. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett. 9, 1\u20136 (1999).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFsrep40095_CR26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bmcl.2008.12.049","volume":"19","author":"LJ Simons","year":"2009","unstructured":"Simons, L. J. et al. The synthesis and structure\u2013activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors. Bioorg. Med. Chem. Lett. 19, 654\u2013657 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFsrep40095_CR27","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1021\/cr000045i","volume":"101","author":"RP Cheng","year":"2001","unstructured":"Cheng, R. P., Gellman, S. H. & DeGrado, W. F. \u03b2-Peptides: From Structure to Function. Chem. Rev. 101, 3219\u20133232 (2001).","journal-title":"Chem. Rev."},{"key":"BFsrep40095_CR28","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1021\/ac800077w","volume":"80","author":"Y Shen","year":"2008","unstructured":"Shen, Y. et al. Mass Spectrometry Analysis of Proteome-Wide Proteolytic Post-Translational Degradation of Proteins. Anal. Chem. 80, 5819\u20135828 (2008).","journal-title":"Anal. Chem."},{"key":"BFsrep40095_CR29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/psc.503","volume":"9","author":"F Formaggio","year":"2003","unstructured":"Formaggio, F. et al. Disruption of the \u03b2-sheet structure of a protected pentapeptide, related to the \u03b2-amyloid sequence 17\u201321, induced by a single, helicogenic C\u03b1-tetrasubstituted \u03b1-amino acid. J. Peptide Sci. 9, 461\u2013466 (2003).","journal-title":"J. Peptide Sci."},{"key":"BFsrep40095_CR30","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1021\/ma00197a010","volume":"22","author":"V Moretto","year":"1989","unstructured":"Moretto, V. et al. Comparison of the Effect of Five Guest Residues on the \u03b2-Sheet Conformation of Host (L-Val)n Oligopeptides. Macromolecules, 22, 2939\u20132944 (1989).","journal-title":"Macromolecules"},{"key":"BFsrep40095_CR31","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.0507471103","volume":"103","author":"LM Yan","year":"2006","unstructured":"Yan, L. M. et al. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. USA 103, 2046\u20132051 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep40095_CR32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymeth.2004.03.012","volume":"34","author":"MR Nilsson","year":"2004","unstructured":"Nilsson, M. R. Techniques to study amyloid fibril formation in vitro . Methods, 34, 151\u2013160 (2004).","journal-title":"Methods"},{"key":"BFsrep40095_CR33","doi-asserted-by":"crossref","first-page":"19279","DOI":"10.1073\/pnas.1305517110","volume":"110","author":"P Cao","year":"2013","unstructured":"Cao, P. et al. Islet amyloid polypeptide toxicity and membrane interactions. Proc. Natl. Acad. Sci. USA 110, 19279\u201319284 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep40095_CR34","doi-asserted-by":"crossref","first-page":"17260","DOI":"10.1021\/la101581g","volume":"26","author":"TL Williams","year":"2010","unstructured":"Williams, T. L., Day, I. J. & Serpell, L. C. The effect of Alzheimer\u2019s A\u03b2 aggregation state on the permeation of biomimetic lipid vesicles. Langmuir, 26, 17260\u201317268 (2010).","journal-title":"Langmuir"},{"key":"BFsrep40095_CR35","doi-asserted-by":"crossref","first-page":"26482","DOI":"10.1074\/jbc.271.43.26482","volume":"271","author":"J McLaurin","year":"1996","unstructured":"McLaurin, J. & Chakrabartty, A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271, 26482\u201326489 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFsrep40095_CR36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s002490000077","volume":"29","author":"M Traikia","year":"2000","unstructured":"Traikia, M. et al. Formation of unilamellar vesicles by repetitive freeze-thaw cycles: characterization by electron microscopy and 31P-nuclear magnetic resonance. Eur. Biophys. J. 29, 184\u2013195 (2000).","journal-title":"Eur. Biophys. J."},{"key":"BFsrep40095_CR37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/1439-7633(20010601)2:6<445::AID-CBIC445>3.0.CO;2-R","volume":"2","author":"J Frackenpohl","year":"2001","unstructured":"Frackenpohl, J. et al. The outstanding biological stability of beta-and gamma-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases. Chembiochem. 2, 445\u2013455 (2001).","journal-title":"Chembiochem."},{"key":"BFsrep40095_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-59745-419-3_10","volume":"494","author":"H Jenssen","year":"2008","unstructured":"Jenssen, H. & Aspmo, S. I. Serum stability of peptides. Methods Mol Biol. 494, 177\u2013186 (2008).","journal-title":"Methods Mol Biol"},{"key":"BFsrep40095_CR39","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/clinchem\/42.4.576","volume":"42","author":"AJ Percy","year":"1996","unstructured":"Percy, A. J. et al. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem. 42, 576\u2013585 (1996).","journal-title":"Clin Chem."},{"key":"BFsrep40095_CR40","first-page":"1831","volume":"75","author":"MC Jones","year":"2007","unstructured":"Jones, M. C. Therapies for diabetes: pramlintide and exenatide. Am. Fam. Physician. 75, 1831\u20131835 (2007).","journal-title":"Am. Fam. Physician."},{"key":"BFsrep40095_CR41","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","volume":"27","author":"GJ Ryan","year":"2005","unstructured":"Ryan, G. J., Jobe, L. J. & Martin, R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther. 27, 1500\u20131512 (2005).","journal-title":"Clin. Ther."},{"key":"BFsrep40095_CR42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","volume":"12","author":"P Hollander","year":"2004","unstructured":"Hollander, P. et al. Effect of Pramlintide on Weight in Overweight and Obese Insulin-Treated Type 2 Diabetes Patients. Obesity 12, 661\u2013668 (2004).","journal-title":"Obesity"},{"key":"BFsrep40095_CR43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-5793(00)01287-4","volume":"470","author":"CE Highama","year":"2000","unstructured":"Highama, C. E. et al. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Letters 470, 55\u201360 (2000).","journal-title":"FEBS Letters"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep40095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40095","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T22:28:36Z","timestamp":1671834516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep40095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,15]]}},"alternative-id":["BFsrep40095"],"URL":"https:\/\/doi.org\/10.1038\/srep40095","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]},"assertion":[{"value":"19 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40095"}}